{"prompt": "['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', 'Table 2 Clinical Laboratory Assessments', 'Hematology', 'Serum Chemistry', 'Full and differential blood count', 'Albumin', 'Hematocrit (Hct)', 'Alanine aminotransferase (ALT)', 'Hemoglobin (Hb)', 'Alkaline phosphatase (ALP)', 'Mean corpuscular hemoglobin', 'Aspartate aminotransferase (AST)', '(MCH)', 'Blood urea nitrogen (BUN) or urea', 'Mean corpuscular hemoglobin', 'Carbon dioxide (CO2', 'concentration (MCHC)', 'Creatinine', 'Mean corpuscular volume (MCV)', 'Creatine kinase and subtypes', 'Platelet count', 'Electrolytes (Na, K, Cl, Ca, P)', 'Red blood cell (RBC) count', 'Gamma-glutamyl transpeptidase (GGT)', 'White blood cell (WBC) count', 'Glucose', 'with differential', 'Lactate dehydrogenase (LDH)', 'Total bilirubin', 'Glycated hemoglobin (HbA1c).', 'Direct bilirubin', '11.4 Adverse Events', '11.4.1 Adverse Events', 'An AE is any symptom, physical sign, syndrome, or disease that either emerges during the', 'study or, if present at screening, worsens during the study, regardless of the suspected cause', 'of the event. All medical and psychiatric conditions (except those related to the indication', 'under study) present at screening will be documented in the medical history eCRF. Changes', 'in these conditions and new symptoms, physical signs, syndromes, or diseases should be', 'noted on the AE eCRF during the rest of the study. Clinically significant laboratory', 'abnormalities should also be recorded as AEs.', 'Adverse device effects (ADEs) are defined as AEs that are considered related to the study', 'device. Possible anticipated ADEs with Prontosan solution or Prontosan gel include burning', 'sensation, itching, and rash. In rare cases (1:10,000), anaphylactic shock has been reported', 'after use of Prontosan solution or Prontosan gel.9,10', 'Patients and/or caregivers will be instructed to report AEs in the diary, and patients will be', 'monitored for AEs at each study visit. All AEs are to be followed until resolution or until a', 'stable clinical endpoint is reached.', 'Each AE is to be documented in the eCRF with reference to start and stop dates, frequency,', 'severity, relationship to study device (related: yes or no), action taken with study device,', 'treatment of event, and outcome. Furthermore, each AE and each ADE are to be classified as', 'being serious or non-serious. Changes in AEs and AE resolution dates are to be documented', 'in the eCRF.', 'For the purposes of this study, the period of observation for collection of AEs extends from', 'the time the patient gives informed consent until the final visit. Follow-up of an AE, even', '14 November 2018', 'Page 43']['B. Braun Medical Inc.', 'OPM-G-H-1506', 'Prontosan', 'Protocol Amendment 2', 'after the end of treatment, is required until the event resolves or stabilizes at a level', 'acceptable to the Investigator.', 'Specific guidelines for classifying AEs by intensity are given in Table 3.', 'Table 3 Classification of Adverse Events by Intensity', 'Mild: An event that is easily tolerated by the patient, causing minimal discomfort and not interfering', 'with everyday activities.', 'Moderate: An event that is sufficiently discomforting to interfere with normal everyday activities.', 'Severe: An event that prevents normal everyday activities.', 'When changes in the intensity of an AE occur more frequently than once a day, the', 'maximum intensity for the event should be noted. If the intensity category changes over a', 'number of days, then those changes should be recorded separately (with distinct onset dates).', '11.4.2 Serious Adverse Events and Serious Adverse Device Effects', 'An AE is considered \"serious\" if in the view of either the Investigator or Sponsor, it meets', '1 or more of the following criteria:', 'Is fatal', 'Is life-threatening', 'Results in inpatient hospitalization or prolongation of existing hospitalization', 'Results in a persistent or significant incapacity or substantial disruption of the ability', 'to conduct normal life functions', 'Is a congenital anomaly/birth defect', 'Other important medical events that may not be immediately life-threatening or result in', 'death or hospitalization, based upon appropriate medical judgment, are considered serious', 'AEs (SAEs) if they are thought to jeopardize the patient and/or require medical or surgical', 'intervention to prevent one of the outcomes defining an SAE.', 'A serious ADE is an ADE that has resulted in any of the consequences characteristic of an', 'SAE.', '11.4.3 Serious Adverse Event Reporting', 'An SAE occurring during the study must be reported to the Sponsor or designee (details for', 'reporting will be in the Safety Plan and on the SAE form). Any such SAE due to any cause,', 'whether or not related to the study device, must be reported within 24 hours of occurrence or', 'when the Investigator becomes aware of the event. Notification can be made with the SAE', 'reporting form as described in the following paragraphs:', '1. Contact the study safety team to inform them that you are faxing an SAE form. The', 'study safety team is available 24 hours a day, 7 days a week. If you are unable to', 'speak with a live safety associate, leave a message with the name of the Investigator,', 'your name, the telephone number where you can be reached, and the protocol number', 'and title.', '2. Fax the SAE form and any supporting documentation to the study safety team within', '24 hours of becoming aware of the event. Verify successful transmission by', '14 November 2018', 'Page 44']\n\n###\n\n", "completion": "END"}